A prediction nomogram for hepatitis B virus-associated hepatocellular carcinoma

References

• El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142(6):1264–1273.e1261. doi: 10.1053/j.gastro.2011.12.061.
   PubMed Web of Science ®Google Scholar
• Papatheodoridis GV, Lampertico P, Manolakopoulos S, et al. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol. 2010;53(2):348–356. doi: 10.1016/j.jhep.2010.02.035.
   PubMed Web of Science ®Google Scholar
• Yang HI, Yuen MF, Chan HL, et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol. 2011;12(6):568–574. doi: 10.1016/S1470-2045(11)70077-8.
   PubMed Web of Science ®Google Scholar
• Wong VW, Chan SL, Mo F, et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol. 2010;28(10):1660–1665. doi: 10.1200/JCO.2009.26.2675.
   PubMed Web of Science ®Google Scholar
• Papatheodoridis G, Dalekos G, Sypsa V, et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. J Hepatol. 2016;64(4):800–806. doi: 10.1016/j.jhep.2015.11.035.
   PubMed Web of Science ®Google Scholar
• Hsu YC, Yip TC, Ho HJ, et al. Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B. J Hepatol. 2018;69(2):278–285. doi: 10.1016/j.jhep.2018.02.032.
   PubMed Web of Science ®Google Scholar
• Jung KS, Kim SU, Song K, et al. Validation of hepatitis B virus-related hepatocellular carcinoma prediction models in the era of antiviral therapy. Hepatology. 2015;62(6):1757–1766. doi: 10.1002/hep.28115.
   PubMed Web of Science ®Google Scholar
• Chen CJ, Yu MW, Liaw YF. Epidemiological characteristics and risk factors of hepatocellular carcinoma. J Gastroenterol Hepatol. 1997;12(9-10):S294–S308. doi: 10.1111/j.1440-1746.1997.tb00513.x.
   PubMed Web of Science ®Google Scholar
• Gao X, Liu W, Yang L, et al. Association between PNPLA3 gene polymorphisms and risk of hepatitis B virus-related hepatocellular carcinoma in Han population in China: a case-control study. Scand J Gastroenterol. 2017;52(10):1120–1127. doi: 10.1080/00365521.2017.1334088.
   PubMed Web of Science ®Google Scholar
• Kawamura A, Matsuda K, Murakami Y, et al. Contribution of an Asian-prevalent HLA haplotype to the risk of HBV-related hepatocellular carcinoma. Sci Rep. 2023;13(1):12944. doi: 10.1038/s41598-023-40000-3.
   PubMed Web of Science ®Google Scholar
• Papatheodoridis GV, Dalekos GN, Yurdaydin C, et al. Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. J Hepatol. 2015;62(2):363–370. doi: 10.1016/j.jhep.2014.08.045.
   PubMed Web of Science ®Google Scholar
• Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2):518–526. doi: 10.1053/jhep.2003.50346.
   PubMed Web of Science ®Google Scholar
• Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317–1325. doi: 10.1002/hep.21178.
   PubMed Web of Science ®Google Scholar
• Xiao G, Yang J, Yan L. Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: a systemic review and meta-analysis. Hepatology. 2015;61(1):292–302. doi: 10.1002/hep.27382.
   PubMed Web of Science ®Google Scholar
• Paik N, Sinn DH, Lee JH, et al. Non-invasive tests for liver disease severity and the hepatocellular carcinoma risk in chronic hepatitis B patients with low-level viremia. Liver Int. 2018;38(1):68–75. doi: 10.1111/liv.13489.
   PubMed Web of Science ®Google Scholar
• Hou J, Wang G, Wang F, et al. Guideline of prevention and treatment for chronic hepatitis B (2015 update). J Clin Transl Hepatol. 2017;5(4):297–318. doi: 10.14218/JCTH.2016.00019.
   PubMed Web of Science ®Google Scholar
• Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–1599. doi: 10.1002/hep.29800.
   PubMed Web of Science ®Google Scholar
• Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–380. doi: 10.1002/hep.29086.
   PubMed Web of Science ®Google Scholar
• Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252–7259. doi: 10.1158/1078-0432.CCR-04-0713.
   PubMed Web of Science ®Google Scholar
• Yuen MF, Tanaka Y, Fong DY, et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol. 2009;50(1):80–88. doi: 10.1016/j.jhep.2008.07.023.
   PubMed Web of Science ®Google Scholar
• Lee MH, Yang HI, Liu J, et al. Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles. Hepatology. 2013;58(2):546–554. doi: 10.1002/hep.26385.
   PubMed Web of Science ®Google Scholar
• Lin Q, Qiu M, Wei X, et al. Genetic variants of SOS2, MAP2K1 and RASGRF2 in the RAS pathway genes predict survival of HBV-related hepatocellular carcinoma patients. Arch Toxicol. 2023;97(6):1599–1611. doi: 10.1007/s00204-023-03469-5.
   PubMedGoogle Scholar
• Yu MC, Yuan J-M, Lu SC. Alcohol, cofactors and the genetics of hepatocellular carcinoma. J Gastroenterol Hepatol. 2008;23 Suppl 1(Suppl 1):S92–S97. doi: 10.1111/j.1440-1746.2007.05293.x.
   PubMedGoogle Scholar
• Fung J, Cheung K-S, Wong DK-H, et al. Long-term outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B e-antigen seroclearance. Hepatology. 2018;68(2):462–472. doi: 10.1002/hep.29874.
   PubMed Web of Science ®Google Scholar
• Lee HW, Park SY, Lee M, et al. An optimized hepatocellular carcinoma prediction model for chronic hepatitis B with well-controlled viremia. Liver Int. 2020;40(7):1736–1743. doi: 10.1111/liv.14451.
   PubMed Web of Science ®Google Scholar
• Sohn W, Cho JY, Kim JH, et al. Risk score model for the development of hepatocellular carcinoma in treatment-naive patients receiving oral antiviral treatment for chronic hepatitis B. Clin Mol Hepatol. 2017;23(2):170–178.; doi: 10.3350/cmh.2016.0086.
   PubMed Web of Science ®Google Scholar
• Chen C-J, Yang H-I, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295(1):65–73. doi: 10.1001/jama.295.1.65.
   PubMed Web of Science ®Google Scholar
• Wong GL, Chan HL, Mak CW, et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology. 2013;58(5):1537–1547. doi: 10.1002/hep.26301.
   PubMed Web of Science ®Google Scholar
• Kim JH, Kim YD, Lee M, et al. Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy. J Hepatol. 2018;69(5):1066–1073. doi: 10.1016/j.jhep.2018.07.018.
   PubMed Web of Science ®Google Scholar
• Wong GL, Chan HL, Wong CK, et al. Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B. J Hepatol. 2014;60(2):339–345. doi: 10.1016/j.jhep.2013.09.029.
   PubMed Web of Science ®Google Scholar
• Li B, Zhang L, Zhang Z, et al. A noninvasive indicator for the diagnosis of early hepatitis B virus-related liver fibrosis. Eur J Gastroenterol Hepatol. 2019;31(2):218–223. doi: 10.1097/MEG.0000000000001281.
   PubMed Web of Science ®Google Scholar
• Kim DY, Kim SU, Ahn SH, et al. Usefulness of FibroScan for detection of early compensated liver cirrhosis in chronic hepatitis B. Dig Dis Sci. 2009;54(8):1758–1763. doi: 10.1007/s10620-008-0541-2.
   PubMed Web of Science ®Google Scholar
• Lee HW, Yoo EJ, Kim BK, et al. Prediction of development of liver-related events by transient elastography in hepatitis B patients with complete virological response on antiviral therapy. Am J Gastroenterol. 2014;109(8):1241–1249. doi: 10.1038/ajg.2014.157.
   PubMed Web of Science ®Google Scholar
• Lesmana CR, Salim S, Hasan I, et al. Diagnostic accuracy of transient elastography (FibroScan) versus the aspartate transaminase to platelet ratio index in assessing liver fibrosis in chronic hepatitis B: the role in primary care setting. J Clin Pathol. 2011;64(10):916–920. doi: 10.1136/jclinpath-2011-200044.
   PubMed Web of Science ®Google Scholar
• Dyson J, Jaques B, Chattopadyhay D, et al. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol. 2014;60(1):110–117. doi: 10.1016/j.jhep.2013.08.011.
   PubMed Web of Science ®Google Scholar